26
Participants
Start Date
October 31, 2016
Primary Completion Date
February 1, 2020
Study Completion Date
March 6, 2020
Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die
Patients enrolled in the study, at the end of the titration phase will be treated with ranolazine 750 mg or 500 mg, 1 oral tablet twice a day for 4 months on top of standard of care treatment
IRCCS Ospedale San Raffaele, Milan
Menarini International Operations Luxembourg SA
INDUSTRY
IRCCS San Raffaele
OTHER